BioGeometryNot yet claimed

About BioGeometry

BioGeometry is a Beijing-based biotechnology company that applies generative AI to protein design. Its GeoBiologics platform pairs AI models with a high-throughput wet-lab validation platform in a design-build-test-learn loop: the models propose proteins, antibodies, vaccines, peptides and enzymes, the lab tests them, and the results retrain the system. Its flagship model family, GeoFlow, is an all-atom generative model for biomolecular structure prediction and de novo design; coverage of its October 2026 funding reported that recent versions added a generate-evaluate-optimise loop, averaged a 20% hit rate across more than 20 targets and found leads within about three weeks — figures reported with the round, not independently verified. A second model, GeoCell, works at cell level, predicting how cells respond to genes and drugs to support target and patient selection.

The company’s own site dates its founding to 2022 (some coverage says 2021). In October 2026 it announced that its Series A rounds had passed US$100 million in total, with a Series A+ extension led by China Life Capital; a pre-A round in 2024 was led by other Chinese investors with an AI company among the participants. Beyond its platform work, the company runs its own programmes: several bispecific-antibody projects are expected to reach IND filing in 2027, and it reports synthetic-biology projects — including a biosynthesised natural compound at sharply lower cost than plant extraction — already through pilot tests, with revenue expected from that side of the business sooner than from drug pipelines.

Products & services

• GeoFlow model family — all-atom generative AI for biomolecular structure prediction and de novo protein and antibody design.
• GeoCell virtual-cell model — predicts cellular responses to genes, drugs and combinations, for target, disease and patient selection.
• GeoBiologics platform — AI-driven macromolecular drug design platform for biomedicine R&D.
• High-throughput wet-lab validation — automated laboratory testing that closes the design-build-test-learn loop with the models.
• Synthetic-biology programmes — engineered production of compounds such as natural borneol (company-reported pilot results).

Why BioGeometry is listed: BioGeometry is one of the clearest tests of whether China’s AI-drug-discovery sector can compete head-on with Western model labs — its published hit-rate claims, its 2027 IND timeline and its state-linked Series A backers are exactly the facts North American pharma and biotech investors need stated carefully, with company claims labelled as such.

How AI assistants describe BioGeometry today

Questions partners ask

GlobleMatch Trust Signals

A directory that doesn’t sell stars. Trust Signals are built only from verifiable facts — never from anonymous ratings, and never for sale. There is no single hidden score.

Public information coverage	8 of 9 fields on the standard profile could be filled from public sources. This counts how much public information exists about the company — not how good the company is. The nine fields are listed in the methodology. Claiming the profile lets the company complete the remaining fields itself.
Last verified	2 November 2026 — facts on this profile were checked against the sources listed below. Profiles are re-checked on a published 90-day cycle; this date is never quietly refreshed.

Claim this profile to unlock response record, directory tenure and peer endorsements. The full methodology — what each signal measures and how it is calculated — is published in the Trust Signals methodology, including a change log.

3 questions to ask this company

1. The 20% hit rate across 20+ targets was reported with the funding round — is that figure from internal programmes, partner programmes, or both, and has any of it been peer-reviewed or published?
2. Your official site dates the founding to 2022 while some coverage says 2021 — which year should partners use?
3. For a Western pharma partner, how do data residency and China’s human-genetic-resources rules shape what a collaboration can look like?

Sources & verification

• Company website — https://www.biogeom.com/about/ (generative-AI protein design, GeoBiologics platform, wet-lab loop, founded in 2022 per the company). Checked 31 Oct 2026.
• Series A coverage, Oct 2026 — https://ventureburn.com/biogeometry-raises-100-million-ai-drug-design-models/ (Beijing-based, Series A+ led by China Life Capital taking Series A past US$100M, GeoFlow and GeoCell, 2027 IND expectations). Checked 31 Oct 2026.
• Founding-year reporting differs (2022 on the company’s site, 2021 in some coverage); this profile follows the company and records the dispute. Performance figures are company-reported.

Facts last verified: 2 November 2026. Something wrong? A listed company can request a correction or removal at any time; verified requests are actioned.

Related companies

More in Health tech: Vitalize (hospital workforce platform, United States) · Confido Health (AI agents for healthcare administration, United States)

More from China: Waffo (global payments platform, China) · Zeroth (home humanoid robots, China)

Country guides: GlobleMatch’s country guides do not cover China yet; when a guide is published, it will list the companies from China in this directory.